Showing results (201-210 of 219) with videos related to

Sort By:
Pageof 22
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Pigment Cell & Melanoma Research|October 7, 2023
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)Alexander Z Wei, Lanyi N Chen, Marlana Orloff, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Frontiers in Immunology|February 11, 2025
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinomaAngela J Yoon, Richard D Carvajal, Evan M Graboyes, et al.
Pageof 22